Eli Lilly Reported Positive Obesity Drug Results

The pharmaceutical company found that its new drug Foundayo lowered cardiovascular risks in a recent clinical trial.

Updated on Oct. 1, 2026 in Diabetes

A close-up of a clear liquid in a glass beaker sitting on a sterile, polished laboratory surface. — Eli Lilly reported positive Phase 3 clinical trial results for Foundayo, showing that the obesity and diabetes drug reduces major cardiovascular risks. AI Illustration. Upload story photo >

Live Poll

Do you believe that new prescription weight-loss medications will lead to better health outcomes for patients?

Eli Lilly announced positive Phase 3 trial results for Foundayo, a treatment for obesity and Type-2 diabetes. The study showed the drug successfully reduced major cardiovascular risks compared to existing treatments.

Why it matters

These results suggest that Foundayo could provide a dual benefit for patients struggling with both metabolic conditions and heart health. By lowering the risk of life-threatening events, the treatment marks a significant development in long-term diabetes management.

In the Phase 3 trial, Foundayo demonstrated a 16% lower risk of major adverse cardiovascular events compared to insulin glargine. Participants also saw a 7-centimeter reduction in waist circumference by the end of the 52-week study period.

The players

Eli Lilly

Eli Lilly is a global pharmaceutical corporation known for developing and marketing medications for diabetes, oncology, and immunology.

The details

The clinical trial compared Foundayo against insulin glargine, observing improvements in both waist circumference and systolic blood pressure in treated participants. The drug showed non-inferiority in preventing cardiovascular events, specifically targeting outcomes like heart attacks and strokes.

At week 52, participants showed improved physical metrics.

Diabetes
Sept. 28
Novo Nordisk Drug Outperformed Tirzepatide in Trials
Weight Loss
Sept. 30
Eli Lilly Reported Results for New Weight-Loss Drug
Diabetes
Sept. 24
FDA Approved Onswik for Type 2 Diabetes

The Big Picture

This discovery updates the clinical expectations set by the broader GLP-1 receptor agonist research pipeline, which has become the industry standard for metabolic treatment. It marks a departure from traditional insulin management by prioritizing heart health outcomes alongside glycemic control.

If approved, Foundayo could offer patients a new treatment option that manages both weight and heart health simultaneously. Patients should consult their healthcare providers about how this development might eventually integrate into their existing diabetes or obesity care plans.

The takeaway

Patients managing Type-2 diabetes may soon have access to therapies that prioritize preventative cardiovascular health alongside blood sugar regulation. Individuals should maintain a regular dialogue with their physicians about emerging treatment options that align with their specific health needs.